BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. [electronic resource]
Producer: 20150214Description: 784-96 p. digitalISSN:- 1097-0215
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Bone Neoplasms -- drug therapy
- Cell Line, Tumor
- Drug Synergism
- Female
- Humans
- Inhibitory Concentration 50
- Male
- Mice, Inbred C57BL
- Mice, Nude
- Osteoblasts -- drug effects
- Osteoclasts -- drug effects
- Osteosarcoma -- drug therapy
- Phosphoinositide-3 Kinase Inhibitors
- Thiazoles -- administration & dosage
- Tumor Burden
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.